Oppenheimer initiated coverage of Inari Medical (NARI) with an Outperform rating and $75 price target Inari is a leader in the thrombectomy for the treatment of deep vein thrombosis and pulmonary embolism, notes the analyst, who says “competition is tough,” but adds that the market is still underpenetrated in the U.S. Ongoing clinical trials provide potential acceleration ahead while Inari also has a number of new opportunities beyond DVT/PE that the firm believes can drive “solid revenue growth and multiple expansion,” the analyst tells investors.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI:
- Inari Medical enters joint venture with 6 Dimensions Capital
- Inari Medical reports PEERLESS study met primary composite endpoint
- Inari Medical price target raised to $50 from $46 at Truist
- Inari Medical price target raised to $74 from $71 at Canaccord
- Inari Medical price target raised to $67 from $66 at Baird